Samsung Biologics Receives 'Negligible Risk' ESG Rating From Sustainalytics

• Samsung Biologics received a “Negligible Risk” ESG rating from Morningstar Sustainalytics on Nov. 3, 2026, improving from “Low Risk.”
• Its ESG risk score of 9.0 places it in the lowest risk category, ranking among the pharmaceutical industry's top 0.5%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611031830PR_NEWS_USPR_____CN87600) on November 03, 2026, and is solely responsible for the information contained therein.